Gain Therapeutics Q1 net loss $0.13/sh; Phase 1b biomarker data support GT-02287

Gain Therapeutics, Inc.

2026-Q1 EPS reported -$0.13

Q1 net loss $0.13 per share vs $0.16; R&D $2.8M, G&A $2.6M; cash $16.5M as of March 31, 2026.
Phase 1b extension for GT-02287 shows GluSph in CSF decreased 81% in elevated baseline participants after 90 days.
MDS-UPDRS scores stable over 150 days; 14 of 16 participants completed five months of dosing as of March 2026.
Expecting FDA IND clearance for GT-02287 in Q2 2026 and Phase 2 start in Q3 2026.
New allosteric modulator GT-04686 ready for IND-enabling studies; presented at AD/PD 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Gain Therapeutics, Inc. reported first quarter ended March 31, 2026 results: EPS $0.13 per share, basic and diluted.

Period: first quarter ended March 31, 2026
EPS: $0.13 per share, basic and diluted
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2026, was $0.13 per share, basic and diluted, compared to $0.16 per share, basic and diluted, for the three months ended March 31, 2025.

View on SEC.gov

170 earnings releases filed in the last 30 days. Browse all earnings releases →

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-058636

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.